Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer

被引：0
|
作者：
Adesoye, Taiwo
Luo, Linjie
Bui, Tuyen
Kim, Serena
Wingate, Hannah
Tripathy, Debu
Hunt, Kelly
Keyomarsi, Khandan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-25-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-25-08
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CDK4/6 inhibition in HER2-positive breast cancer Comment
    Battisti, Nicolo Matteo Luca
    Ring, Alistair
    LANCET ONCOLOGY, 2020, 21 (06): : 734 - 735
  • [2] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [3] The emerging role of CDK4/6i in HER2-positive breast cancer
    O'Sullivan, Ciara C.
    Suman, Vera J.
    Goetz, Matthew P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [4] STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition
    Kettner, Nicole M.
    Bui, Tuyen
    Ha, Min Jin
    Eckols, T. Kris
    Tweardy, David J.
    Meric-Bernstam, Funda
    Hunt, Kelly K.
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [5] CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Zhang, Kai
    Hong, Ruoxi
    Kaping, Lee
    Xu, Fei
    Xia, Wen
    Qin, Ge
    Zheng, Qiufan
    Lu, Qianyi
    Zhai, Qinglian
    Shi, Yanxia
    Yuan, Zhongyu
    Deng, Wuguo
    Chen, Miao
    Wang, Shusen
    CANCER LETTERS, 2019, 447 : 130 - 140
  • [6] The Role of CDK4/6 Inhibition in Breast Cancer
    Murphy, Conleth G.
    Dickler, Maura N.
    ONCOLOGIST, 2015, 20 (05): : 483 - U49
  • [7] Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
    Goel, Shom
    Wang, Qi
    Watt, April C.
    Tolaney, Sara M.
    Dillon, Deborah A.
    Li, Wei
    Ramm, Susanne
    Palmer, Adam C.
    Yuzugullu, Haluk
    Varadan, Vinay
    Tuck, David
    Harris, Lyndsay N.
    Wong, Kwok-Kin
    Liu, X. Shirley
    Sicinski, Piotr
    Winer, Eric P.
    Krop, Ian E.
    Zhao, Jean J.
    CANCER CELL, 2016, 29 (03) : 255 - 269
  • [8] CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer
    Agostinetto, Elisa
    Debien, Veronique
    Marta, Guilherme Nader
    Lambertini, Matteo
    Piccart-Gebhart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (07)
  • [9] Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer.
    ElChaarani, Bilal
    Stires, Hillary
    Pohlmann, Paula Raffin
    Riggins, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
    Jeong, Yisun
    Kim, Hyungjoo
    You, Daeun
    Cho, Soo Youn
    Yoon, Sun Young
    Kim, Seok Won
    Nam, Seok Jin
    Lee, Jeong Eon
    Kim, Sangmin
    CELLS, 2025, 14 (01)
12345